Skip to content

A Randomized Cross Over Trial of Two Treatments for Sleep Apnea in Veterans With Post-Traumatic Stress Disorder

A Randomized Cross Over Trial of Two Treatments for OSA in Veterans With PTSD

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01569022
Enrollment
42
Registered
2012-04-02
Start date
2012-11-01
Completion date
2017-03-30
Last updated
2017-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea

Keywords

post traumatic stress disorder, continuous positive airway pressure, oral appliance

Brief summary

Sleep disturbances are cardinal features of Veterans with post traumatic stress disorder (PTSD). In particular, obstructive sleep apnea is reported to occur more frequently in patients with PTSD compared to those without PTSD and contribute to worsening cognitive and behavioral functions. Continuous positive airway pressure (CPAP) is considered the treatment of choice for OSA but adherence to CPAP in Veterans with PTSD is poor compared to the general population. The proposed study aims at comparing the efficacy, tolerability, and adherence of oral appliances-an alternative therapy to OSA- to CPAP. The study is instrumental in identifying the optimal OSA therapy for Veterans with PTSD and the OSA phenotype that would predict oral appliance response

Detailed description

Obstructive sleep apnea (OSA) is a prevalent disorder associated with poor neurocognitive performance and organ system dysfunction due to intermittent hypoxia and repeated arousals. The repetitive hemodynamic stresses are implicated in the increased incidence of systemic hypertension and cardiovascular diseases. Insufficient and disrupted sleep has similar negative impact on mood, attention, cognition, and behavior. In Veterans with post traumatic stress disorder (PTSD), the disturbed sleep can worsen further the cognitive-behavioral manifestations of PTSD and contributes to poor mental and physical health outcomes. Recent epidemiologic studies largely support the association of higher rates of OSA in patients with PTSD compared with the general population. Treatment of the underlying obstructive sleep disturbances with continuous positive airway pressure (CPAP) has resulted in restoration of sleep architecture, decrease daytime sleepiness, and reduction in nightmares frequency and intensity. However, adherence to treatment with CPAP is less than optimal in Veterans with PTSD. Mandibular advancing devices (MADs) are considered non surgical alternatives to CPAP and are preferred in a head to head comparison to CPAP in OSA subjects without PTSD. However, there has been no study to the investigators' knowledge that has assessed MAD in terms of clinical efficacy, compliance, and quality of sleep compared to CPAP in OSA patients with PTSD. Therefore, the investigators hypothesize that MAD is not inferior to CPAP in treating OSA effectively in Veterans with PTSD and OSA. To that end, the investigators propose to conduct a feasibility study using a randomized crossover trial of 12 weeks of CPAP and MAD in 42 consecutive outpatients with PTSD newly diagnosed with OSA separated by 2 weeks washout period. The primary endpoint of the trial is to compare the treatment efficacy of CPAP and MAD in Veterans with PTSD and OSA. Secondary endpoints aim at: 1) comparing change in the Epworth Sleepiness Scale, SF-36, and the Pittsburgh Sleep Quality Index at end of treatment following use of CPAP versus MAD, 2) comparing adherence and short-term side effects between using CPAP and MAD in PTSD patients with OSA, and 3) determining anthropomorphic, polysomnographic, and cephalometric predictors of successful MDA response. Assessments at the end of both limbs comprise evaluation of quality of sleep, daytime sleepiness, quality of life, and side effects of treatment. Compliance with each therapy will be measured at the end of each treatment period. The results of the trial are pivotal in determining the efficacy, tolerability, and adherence to MAD compared to CPAP in Veterans with PTSD and OSA. This feasibility study would form the basis of a future trial examining the effectiveness of various therapeutic modalities for OSA on PTSD symptomatology and progression.

Interventions

DEVICECPAP

CPAP Treatment for 12 weeks

DEVICEMAD

MAD Treatment for 12 weeks

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

randomized trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Consecutive patients aged 18-70 years of age * Documented obstructive sleep apnea by polysomnography (AHI 5 or more/hr) * Established diagnosis of PTSD related to any past lifetime traumatic event and have a diagnosis of current, chronic PTSD

Exclusion criteria

* Central sleep apnea defined as central apnea/hypopnea \>50% of the total respiratory events * Prior treatment for sleep apnea * Veterans with fewer than 4 teeth remaining in either arch * Coexisting narcolepsy * Tempo-mandibular joint disease * Epilepsy * Prominent suicidal or homicidal ideation * Diagnosis of dementia

Design outcomes

Primary

MeasureTime frameDescription
Residual Apnea Hypopnea Indexup to 12 weeksThe primary endpoint of the study was tested by comparing the upper limit of the 95% confidence interval for the CPAP-MAD difference in residual AHI with the a priori noninferiority margin using the paired t test

Secondary

MeasureTime frameDescription
Health Outcomes12 weeksHealth outcomes including ESS, PCL-M, and PSQI. ESS is a short questionnaire validated to measure excessive daytime sleepiness in patients with OSA 17. It measures the likelihood of falling asleep in eight different situations, with a score of 0-3 for each situation. The sum of individual scores for the eight items gives the final ESS score, ranging from 0-21. An ESS score \>10 suggests excessive daytime sleepiness (EDS). The PSQI is a self-rating questionnaire that consists of seven dimensions. The possible scores range from 0-21, with greater than five indicative of impaired sleep quality. The PTSD Checklist is a 17-item self-report measure (1-5 points each) that assesses PTSD symptoms in relation to stressful military experiences. PTSD symptom severity scores are determined by summing the participants' answers to all 17 items from 1 (not at all) to 5 (extremely)(range 17-85) 14 with 5-10 point change indicating statistically significant response to treatment
General Health SF-3612 weeksThe SF-36 is a generic 36-item Short Form Medical Outcomes Survey (SF-36) 16. It has eight main domains: physical functioning, role limitation due to physical problems, role limitation due to emotional problems, social functioning, mental health, energy/vitality, bodily pain, and general health perception. General Health SF36 score is coded, summed, and transformed onto a scale from 0 to 100 (worst to best possible health).
Adherence to Therapy12 weekscomparison of the number of hours per night used while on CPAP versus MAD

Countries

United States

Participant flow

Recruitment details

A total of 127 Veterans were considered for study participation between August 2013 and April 2016. Fifty-four patients agreed to enroll in the study but twelve patients either failed to return for scheduled visits or withdrew from further participation because of lack of time or other pressing matters. Forty-two were randomized to CPAP or MAD.

Participants by arm

ArmCount
All Study Participants
Participants were asked to acclimate to CPAP and MAD for 4 weeks (total) during which adjustments to both modes of therapy are made aiming to optimize comfort and abolish snoring. If the interface was found to be uncomfortable, the patient was given the opportunity to change the mask. None of the participants was exposed to dual therapy or had access to both devices at the same time. Weekly phone calls were made to inquire about side effects or problems with CPAP or MAD. At the end of the acclimatization period, patients underwent a 2-week washout, after which they were randomly assigned in 1:1 ratio via a presealed and numbered opaque white envelope to one of the two treatment modalities (CPAP or MAD) that included the assignment to receive 12 weeks of treatment with MAD and CPAP in alternating order
35
Total35

Withdrawals & dropouts

PeriodReasonFG000FG001
First InterventionLost to Follow-up21
Second InterventionLost to Follow-up22

Baseline characteristics

CharacteristicAll Study Participants
Age, Continuous52.7 years
STANDARD_DEVIATION 11.6
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
5 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
30 Participants
Sex: Female, Male
Female
5 Participants
Sex: Female, Male
Male
30 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
26 / 3514 / 35
serious
Total, serious adverse events
0 / 350 / 35

Outcome results

Primary

Residual Apnea Hypopnea Index

The primary endpoint of the study was tested by comparing the upper limit of the 95% confidence interval for the CPAP-MAD difference in residual AHI with the a priori noninferiority margin using the paired t test

Time frame: up to 12 weeks

ArmMeasureValue (MEAN)Dispersion
CPAPResidual Apnea Hypopnea Index3.9 events per hourStandard Deviation 4.8
Mandibular Advancing DeviceResidual Apnea Hypopnea Index26.3 events per hourStandard Deviation 25.6
p-value: <0.001t-test, 2 sided
Secondary

Adherence to Therapy

comparison of the number of hours per night used while on CPAP versus MAD

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
CPAPAdherence to Therapy3.4 hours per nightStandard Deviation 2.48
Mandibular Advancing DeviceAdherence to Therapy5.66 hours per nightStandard Deviation 2.43
p-value: <0.001t-test, 2 sided
Secondary

General Health SF-36

The SF-36 is a generic 36-item Short Form Medical Outcomes Survey (SF-36) 16. It has eight main domains: physical functioning, role limitation due to physical problems, role limitation due to emotional problems, social functioning, mental health, energy/vitality, bodily pain, and general health perception. General Health SF36 score is coded, summed, and transformed onto a scale from 0 to 100 (worst to best possible health).

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
CPAPGeneral Health SF-3649.33 units on a scaleStandard Deviation 17.09
Mandibular Advancing DeviceGeneral Health SF-3650.58 units on a scaleStandard Deviation 15.45
p-value: 0.54t-test, 2 sided
Secondary

Health Outcomes

Health outcomes including ESS, PCL-M, and PSQI. ESS is a short questionnaire validated to measure excessive daytime sleepiness in patients with OSA 17. It measures the likelihood of falling asleep in eight different situations, with a score of 0-3 for each situation. The sum of individual scores for the eight items gives the final ESS score, ranging from 0-21. An ESS score \>10 suggests excessive daytime sleepiness (EDS). The PSQI is a self-rating questionnaire that consists of seven dimensions. The possible scores range from 0-21, with greater than five indicative of impaired sleep quality. The PTSD Checklist is a 17-item self-report measure (1-5 points each) that assesses PTSD symptoms in relation to stressful military experiences. PTSD symptom severity scores are determined by summing the participants' answers to all 17 items from 1 (not at all) to 5 (extremely)(range 17-85) 14 with 5-10 point change indicating statistically significant response to treatment

Time frame: 12 weeks

ArmMeasureGroupValue (MEAN)Dispersion
CPAPHealth OutcomesPitt sleep quality index17.3 units on a scaleStandard Deviation 0.2
CPAPHealth OutcomesEpworth Sleepiness Scale9.4 units on a scaleStandard Deviation 4.7
CPAPHealth OutcomesPTSD Checklist49.9 units on a scaleStandard Deviation 15.4
Mandibular Advancing DeviceHealth OutcomesEpworth Sleepiness Scale9.5 units on a scaleStandard Deviation 4.9
Mandibular Advancing DeviceHealth OutcomesPTSD Checklist50.03 units on a scaleStandard Deviation 13.64
Mandibular Advancing DeviceHealth OutcomesPitt sleep quality index17.3 units on a scaleStandard Deviation 0.2
Comparison: ESSp-value: 0.97t-test, 2 sided
Comparison: PCLp-value: 0.98t-test, 2 sided
Comparison: PSQIp-value: 0.31t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026